Skip to main content
Keystone plans clinical testing of 3rd-gen embolic protection device
8/3/2017

Israel-based Keystone Heart said it intends to initiate trials of its TriGuard 3 third-generation cerebral embolic protection device by year's end. Features include anatomical independence and an over-the-wire design on an 8 French sheath, and the design prevents contact with cerebral branch vessels.

Full Story: